ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article

Ann Thorac Surg 1995;60:244
© 1995 The Society of Thoracic Surgeons

Discussion

Discussion

The first 20% of the full text of this article appears below.

See also page 239.

DR THOMAS M. EGAN (Chapel Hill, NC): What do you think the cardiac toxicity would be in vivo, and have you looked at that in any surviving rats that you have perfused?

DR PORT: There is evidence that glutathione may provide cardioprotection from agents such as doxorubicin. Therefore, there has been considerable hesitancy in using BSO, an inhibitor of glutathione, with systemic doxorubicin therapy. We have demonstrated in our model of isolated lung perfusion . . . [Full Text of this Article]


Related Article

Buthionine Sulfoximine Pretreatment Potentiates the Effect of Isolated Lung Perfusion With Doxorubicin
Jeffrey L. Port, Steven N. Hochwald, Hong-Yue Wang, and Michael E. Burt
Ann. Thorac. Surg. 1995 60: 239-243. [Abstract] [Full Text]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1995 by The Society of Thoracic Surgeons.